Login to Your Account



FDA Panel Unanimously Backs Theratechnologies VAT Drug

By Donna Young


Friday, May 28, 2010
ADELPHI, Md. - An FDA panel Thursday said the benefits of Theratechnologies Inc.'s Egrifta (tesamorelin acetate) in reducing excess abdominal fat in HIV-infected patients with lipodystrophy outweighed the drug's potential risks of diabetes and cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription